It was April 2009, and the virus was wholly unique, a reassortment of influenza viral components never before seen in humans or animals. The first cases identified were in California, and, though they were infected with a swine-lineage virus, lacked a reassuring exposure to pigs, transforming the scenario from zoonotic curiosity to pandemic concern.²

Identified as influenza A(H1N1), the virus soon became expansive in its extent. By the end of April, it transpired that cases in Mexico had predated the California cases, and the Centers for Disease Control and Prevention (CDC) recommended the delay of all non-essential travel to Mexico. By June there were an estimated 1 million cases in the United States, the virus was spreading to other world regions, and the World Health Organization declared a pandemic.¹ Successive waves of illness in summer and fall swept across the country. Schools and summer camps closed; hospitals braced for high patient loads and staff shortages. The U.S. Food and Drug Administration approved new H1N1 vaccines in September, and a major vaccination campaign, prioritizing higher-risk individuals, was underway by October, just as the second wave of influenza activity was cresting. CDC estimates that during April 2009–August 2010, 151,700–575,400 people died, more than half of them in Africa and Southeast Asia. Strikingly, most of the people who died were younger adults: 65% of deaths were in adults ages 18–64, compared to the typical seasonal flu, in which 80%–90% of fatal cases are adults ≥65 years of age.²

The 2009 H1N1 virus persisted through the next 10 flu seasons, sometimes as the predominant strain, sometimes as a secondary menace. CDC estimates that during its 2009–2018 existence, the A H1N1 pdm09 virus has caused 100.5 million illnesses, 936,000 hospitalizations, and 75,000 deaths in the United States.³

While remaining vigilant in surveillance and diligent in preparation for the next great pandemic, we must remember how disruptive plain old seasonal flu can be. Let us recall, therefore, the most recent season and look toward the next.

2018–2019 SEASON REVIEW

The 2018–2019 flu season peaked in mid-March. At its apex, 4.8% of all emergency department (ED) visits in Oregon were for influenza-like illness (ILI), according to ESSENCE syndromic surveillance data (Figure, verso). The previous two seasons peaked in January. By contrast, the fall peak of ILI activity during the 2009 H1N1 pandemic in Oregon was in mid-October, when seasonal influenza activity is typically just beginning to be detected. During that peak, 8.5% of all ED visits were for ILI, an alarming figure.

In the Portland tri-county area, 1,305 people were hospitalized with flu during the 2018–2019 season, and 53 of them died (case-fatality rate 4.1%). More than 99% (1,298) of hospitalized cases had influenza A. Of the 406 that were subtyped, 163 (40%) were A(H1N1) pdm09, and 243 (60%) were A(H3N2). Although hospitalizations were fewer than in the previous two seasons (1,522 in the 2017–2018 season and 1,466 in the 2016–2017 season), the death toll was similar. Flu A(H3N2), generally associated with higher mortality than A(H1N1), was the predominant strain during all three seasons. By comparison, during the 2009–2010 pandemic season, 2.6% of hospitalized patients were hospitalized or who died from radiographically or histologically demonstrated lung injury following a history of e-cigarette use or vaping in the preceding 90 days. Reports may be made to the local public health authority; or to the Oregon Health Authority (phone 971-673-1111; fax 971-673-1100); or on-line at http://healthoregon.org/onlinemorbidityform.*

We appreciate your reporting anyone who dies or is hospitalized with vaping-associated lung injury. It helps us to systematically identify those affected by the condition so that we can investigate potential causes of injury, assess the risk to the public, and recommend appropriate preventive action.

Please report within one working day any patient who has been hospitalized or who died from radiographically or histologically demonstrated lung injury following a history of e-cigarette use or vaping in the preceding 90 days. Reports may be made to the local public health authority; or to the Oregon Health Authority (phone 971-673-1111; fax 971-673-1100); or on-line at http://healthoregon.org/onlinemorbidityform.*

Emergency Rule: Hospitalization or death due to vaping-associated lung injury (VALI)

In response to the Governor’s Executive Order 19-09, the Oregon Health Authority has set forth an emergency rule to mandate reporting of hospitalization or death due to vaping-associated lung injury, effective October 9, 2019. A national outbreak of vaping-associated lung injury was recently identified by the Centers for Disease Control and Prevention (CDC), with 1,299 cases reported from 49 states, the District of Columbia and one U.S. territory as of October 8; 26 deaths have been confirmed in 21 states.* We appreciate your reporting anyone who dies or is hospitalized with vaping-associated lung injury. It helps us to systematically identify those affected by the condition so that we can investigate potential causes of injury, assess the risk to the public, and recommend appropriate preventive action.

2019–2020 FLU SEASON VACCINE AND UPDATES

While the viral descendants of pandemic A(H1N1) continue to circulate alongside the variations of A(H3N2), let us turn now to the season at hand. The 2019–2020 U.S. influenza vaccine features updated flu A(H1N1) and A(H3N2) components, as along with last year’s B component(s).4

All available regular-dose vaccines will be quadrivalent this season and, as in the previous season, live attenuated influenza vaccine (LAIV or FluMist®) is back in rotation. CDC is unwavering in its recommendation that all persons ≥6 months of age without a contraindication should receive annual flu vaccination. The only absolute contraindication to influenza vaccination is a previous severe allergic reaction to the influenza vaccine itself (or to one of its components). Cautious providers may consider having patients stay for 15 minutes seated observation following vaccine administration — an ACIP best practice recommendation for the administration of all vaccines to guard against syncope-associated injury, which is most likely to occur in the 15 minutes following vaccine administration, particularly among adolescents.5

Though all people would benefit from the protection offered by the flu vaccine, certain groups are at increased risk of complications from influenza disease: children <5 years (and especially <2 years) of age, adults ≥50 years (and especially ≥65 years), persons with chronic health conditions, immunocompromised persons, pregnant and postpartum women, and people living in congregate settings. Furthermore, people who live with or take care of any of these high-risk groups should also be prioritized for vaccination. Any age-appropriate inactivated influenza vaccine or recombinant influenza vaccine may be used with any of these groups, but LAIV is not recommended for immunocompromised persons, close contacts of severely immunosuppressed persons, pregnant women, kids 2–4 years of age with asthma, kids of any age receiving salicylates (aspirin), or persons who have received influenza antiviral medications in the previous 48 hours.4 Children <9 years of age who have received <2 lifetime doses of influenza vaccine should receive 2 doses given ≥4 weeks apart; ACIP recently clarified that if a child turns 9 during those 4 weeks, he or she should receive the second dose.4

Several studies, including one using data from Portland-area flu hospitalizations and our state immunization registry, show that high-dose vaccines reduce the risk of influenza illness and hospitalization in older adults as compared to standard-dose vaccines.7,9 The adjuvanted vaccine may also protect older adults better than standard dose, non-adjuvanted vaccines.10

PROTECTING PREGNANT WOMEN

Pregnant and postpartum women are at increased risk of distressing flu complications such as pneumonia, but nevertheless remain undervaccinated. Indeed, over the last five years of surveillance for hospitalized influenza in the Portland Metro area, less than half of pregnant women had received a flu vaccine — well short of the 80% target set by Healthy People 2020.11 Influenza vaccination must be seen as a critical component of prenatal care.

Pregnant women and those ≤2 weeks postpartum with early signs of influenza illness should be evaluated immediately and treated presumptively for influenza with antiviral medications (oral oseltamivir is preferred), without waiting for laboratory confirmation and without regard for vaccination history. The American College of Obstetricians and Gynecologists (ACOG) recommends antiviral treatment even if more than 2 days have elapsed since symptom onset.12 Lastly, if a woman who is pregnant or ≤2 weeks postpartum is exposed via close contact to someone who likely has the flu, ACOG recommends that postexposure antiviral chemoprophylaxis be considered regardless of vaccination status; CDC, however, would take vaccination status into account.11,13

Whether seasonal or pandemic, influenza can cut great swaths of illness through the community. Handwashing and cough covering are important everyday precautions, but for the best shot at protection — before the end of October — get your flu shot!

FOR MORE INFORMATION
• CDC FluView: https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html
• Oregon Immunization Program Maternal Immunization Toolkit: www.oregon.gov/oha/PH/PREVENTIONWELLNESS/VACCINES/IMMUNIZATION/IMMUNIZATIONPROVIDERRESOURCES/Pages/maternalimm.aspx
• ACOG Maternal Immunization Tool Kit: https://immunizationforwomen.org/providers/resources/toolkits/maternalimmunizations.php
REFERENCES


